company background image
MRNS

Marinus Pharmaceuticals NasdaqGM:MRNS Stock Report

Last Price

US$7.32

Market Cap

US$399.2m

7D

16.1%

1Y

58.0%

Updated

04 Dec, 2023

Data

Company Financials +

Marinus Pharmaceuticals, Inc.

NasdaqGM:MRNS Stock Report

Mkt Cap: US$399.2m

MRNS Stock Overview

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders.

MRNS fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Marinus Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Marinus Pharmaceuticals
Historical stock prices
Current Share PriceUS$7.32
52 Week HighUS$11.15
52 Week LowUS$3.47
Beta1.11
1 Month Change4.80%
3 Month Change-1.15%
1 Year Change57.99%
3 Year Change-53.14%
5 Year Change-65.10%
Change since IPO-77.14%

Recent News & Updates

Recent updates

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Sep 22
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Using Debt Sensibly?

Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Jun 12
Why Investors Shouldn't Be Surprised By Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) P/S

Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

May 16
Forecast: Analysts Think Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Business Prospects Have Improved Drastically

Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Oct 26
Analysts Just Made A Major Revision To Their Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenue Forecasts

Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Oct 12
Is Marinus Pharmaceuticals (NASDAQ:MRNS) Weighed On By Its Debt Load?

Marinus Pharmaceuticals: Positive News Flow Of Note

Sep 22

Marinus Pharma closes on sale of a U.S. FDA priority review voucher for $110M

Aug 29

Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Aug 13
Analysts' Revenue Estimates For Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Are Surging Higher

Marinus Pharmaceuticals Q2 2022 Earnings Preview

Aug 10

Marinus Pharma announces U.S. commercial launch of seizure therapy Ztalmy

Jul 28

Revisiting Marinus Pharmaceuticals

May 05

Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Mar 27
Need To Know: Analysts Are Much More Bullish On Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Revenues

Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Mar 03
Does Marinus Pharmaceuticals (NASDAQ:MRNS) Have A Healthy Balance Sheet?

Marinus Stock Slides To 18-Month Low, Upcoming PDUFA May Offer Redemption

Feb 28

Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?

Nov 04
Health Check: How Prudently Does Marinus Pharmaceuticals (NASDAQ:MRNS) Use Debt?

Marinus Pharmaceuticals (MRNS) Investor Presentation - Slideshow

May 26

We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely

Apr 14
We're Hopeful That Marinus Pharmaceuticals (NASDAQ:MRNS) Will Use Its Cash Wisely

Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share Price

Mar 10
Marinus Pharmaceuticals, Inc.'s (NASDAQ:MRNS) Intrinsic Value Is Potentially 53% Above Its Share Price

Marinus Pharma's one late-stage ganaxolone study sufficient for US application for a type of epilepsy

Jan 13

Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?

Jan 07
Is Marinus Pharmaceuticals (NASDAQ:MRNS) In A Good Position To Invest In Growth?

Shareholder Returns

MRNSUS PharmaceuticalsUS Market
7D16.1%-0.2%1.1%
1Y58.0%-4.5%11.7%

Return vs Industry: MRNS exceeded the US Pharmaceuticals industry which returned -4.5% over the past year.

Return vs Market: MRNS exceeded the US Market which returned 11.7% over the past year.

Price Volatility

Is MRNS's price volatile compared to industry and market?
MRNS volatility
MRNS Average Weekly Movement12.0%
Pharmaceuticals Industry Average Movement10.8%
Market Average Movement6.1%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: MRNS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: MRNS's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2003152Scott Braunsteinhttps://marinuspharma.com

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.

Marinus Pharmaceuticals, Inc. Fundamentals Summary

How do Marinus Pharmaceuticals's earnings and revenue compare to its market cap?
MRNS fundamental statistics
Market CapUS$399.21m
Earnings (TTM)-US$133.61m
Revenue (TTM)US$30.96m

12.9x

P/S Ratio

-3.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
MRNS income statement (TTM)
RevenueUS$30.96m
Cost of RevenueUS$95.77m
Gross Profit-US$64.81m
Other ExpensesUS$68.80m
Earnings-US$133.61m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.45
Gross Margin-209.32%
Net Profit Margin-431.55%
Debt/Equity Ratio196.6%

How did MRNS perform over the long term?

See historical performance and comparison